CA3150508A1 - Azole-fused pyridazin-3(2h)-one derivatives - Google Patents

Azole-fused pyridazin-3(2h)-one derivatives Download PDF

Info

Publication number
CA3150508A1
CA3150508A1 CA3150508A CA3150508A CA3150508A1 CA 3150508 A1 CA3150508 A1 CA 3150508A1 CA 3150508 A CA3150508 A CA 3150508A CA 3150508 A CA3150508 A CA 3150508A CA 3150508 A1 CA3150508 A1 CA 3150508A1
Authority
CA
Canada
Prior art keywords
oxo
pyrazolo
dihydro
methy1
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3150508A
Other languages
English (en)
French (fr)
Inventor
Holger Monenschein
Sean Murphy
Scott Olsen
Natasha O'ROURKE
Holly REICHARD
Melinda DAVIS
Betty Lam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA3150508A1 publication Critical patent/CA3150508A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3150508A 2019-09-16 2020-09-15 Azole-fused pyridazin-3(2h)-one derivatives Pending CA3150508A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901052P 2019-09-16 2019-09-16
US62/901,052 2019-09-16
PCT/US2020/050823 WO2021055326A1 (en) 2019-09-16 2020-09-15 Azole-fused pyridazin-3(2h)-one derivatives

Publications (1)

Publication Number Publication Date
CA3150508A1 true CA3150508A1 (en) 2021-03-25

Family

ID=72670806

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3150508A Pending CA3150508A1 (en) 2019-09-16 2020-09-15 Azole-fused pyridazin-3(2h)-one derivatives

Country Status (25)

Country Link
US (1) US12370192B2 (https=)
EP (1) EP4031552B1 (https=)
JP (1) JP7566888B2 (https=)
KR (1) KR102924294B1 (https=)
CN (1) CN114728975A (https=)
AR (1) AR119971A1 (https=)
AU (1) AU2020348675B2 (https=)
BR (1) BR112022004819A2 (https=)
CA (1) CA3150508A1 (https=)
CO (1) CO2022004684A2 (https=)
CR (1) CR20220160A (https=)
DO (1) DOP2022000057A (https=)
EC (1) ECSP22020159A (https=)
ES (1) ES2997267T3 (https=)
HR (1) HRP20250088T1 (https=)
HU (1) HUE069908T2 (https=)
IL (1) IL291181B2 (https=)
JO (1) JOP20220063A1 (https=)
MX (1) MX2022003177A (https=)
PE (1) PE20221341A1 (https=)
PH (1) PH12022550597A1 (https=)
PL (1) PL4031552T3 (https=)
RS (1) RS66463B1 (https=)
TW (1) TWI873185B (https=)
WO (1) WO2021055326A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CR20220160A (es) 2019-09-16 2022-06-16 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
WO2021224680A1 (en) 2020-05-08 2021-11-11 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a gpr139 agonist
GB202106872D0 (en) * 2021-05-13 2021-06-30 Addex Pharmaceuticals Sa Novel compounds
CN114149371B (zh) * 2021-11-26 2023-08-22 首都医科大学 四取代吡唑类化合物及其应用
CN116693545A (zh) * 2022-03-01 2023-09-05 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
CN116693536A (zh) * 2022-03-01 2023-09-05 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3
CN116063179A (zh) * 2023-02-20 2023-05-05 南京杰运医药科技有限公司 一种4-甲氧基乙酰乙酸甲酯的合成方法
WO2025119351A1 (zh) * 2023-12-08 2025-06-12 深圳湾实验室 Gpr139激动剂
WO2025124544A1 (zh) * 2023-12-14 2025-06-19 华润医药研究院（深圳）有限公司 3,4-二氢-2H-苯并[b][1,4]二氧杂环庚烷类化合物及其制备方法和医药用途
WO2025162441A1 (zh) * 2024-02-02 2025-08-07 上海科技大学 稠杂环类化合物与其制备方法、药物组合物及应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
WO1987004928A1 (fr) 1986-02-24 1987-08-27 Mitsui Petrochemical Industries, Ltd. Agents therapeutiques de la neuropathie
EP0315390B1 (en) 1987-11-04 1994-07-20 Beecham Group Plc Novel 4-oxobenzotriazines and 4-oxoquinazolines
JPH0285851A (ja) 1988-09-22 1990-03-27 Konica Corp 新規な写真用カプラー
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JP2874960B2 (ja) 1990-06-03 1999-03-24 コニカ株式会社 新規な染料を含有するハロゲン化銀写真感光材料
JPH04119890A (ja) 1990-09-11 1992-04-21 Konica Corp ピラゾロチアジアジン系色素
JP3430375B2 (ja) 1993-11-12 2003-07-28 コニカ株式会社 感熱転写材料及び該材料に好適な色素
DE4339868A1 (de) * 1993-11-23 1995-05-24 Merck Patent Gmbh Imidazopyridazine
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
DE19704923A1 (de) 1997-02-10 1998-08-13 Hoechst Schering Agrevo Gmbh Klebstoffhaltige Schädlingsbekämpfungsmittel
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CN1293665A (zh) 1998-02-18 2001-05-02 神经研究公司 新化合物及其用作阳性ampa受体调节剂
AU1153601A (en) 1999-10-29 2001-05-08 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
JP2003526341A (ja) 1999-11-04 2003-09-09 コロラド ステート ユニバーシティー リサーチ ファウンデーション 昆虫を誘引するための装置および方法
FR2801587B1 (fr) 1999-11-30 2002-01-11 Adir Nouveaux derives de benzothiadiazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2002085851A (ja) 2000-09-19 2002-03-26 Totan Information Technology Kk 経済指標予想ゲームシステム
MXPA04003297A (es) 2001-10-10 2004-07-23 Neurosearch As Derivados novedosos de benzotiacina su preparacion y uso.
FR2833955B1 (fr) 2001-12-21 2004-01-30 Servier Lab Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003235121A1 (en) 2002-04-26 2003-11-10 Takeda Pharmaceutical Company Limited Novel thiol derivative, process for producing the same and use thereof
JP4079727B2 (ja) 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
JP3981316B2 (ja) 2002-09-27 2007-09-26 京セラ株式会社 半導体素子収納用パッケージ
FR2854634B1 (fr) 2003-05-05 2005-07-08 Servier Lab Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
AU2004261283B2 (en) 2003-07-31 2008-05-01 Irm, Llc Bicyclic compounds and compositions as PDF inhibitors
FR2865474B1 (fr) 2004-01-26 2008-06-13 Servier Lab Nouveaux derives de benzothiazines fluorees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
FR2879201B1 (fr) 2004-12-10 2007-02-16 Servier Lab Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4738988B2 (ja) 2005-11-17 2011-08-03 花王株式会社 ２連式吐出器
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
AU2007262661A1 (en) 2006-06-23 2007-12-27 Nufarm Australia Limited Phenoxy alkanoate herbicidal composition and method of preparation and use
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
FR2909090B1 (fr) 2006-11-23 2009-01-09 Sanofi Aventis Sa Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
WO2008073789A1 (en) 2006-12-11 2008-06-19 Eli Lilly And Company Ampa receptor potentiators
US20080167374A1 (en) 2007-01-09 2008-07-10 Loveland Products, Inc. Pesticide composition and method of use
US8148367B2 (en) 2007-01-12 2012-04-03 Takeda Pharmaceutical Company Limited Renin inhibitors
WO2008094556A2 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
MX2010005028A (es) 2007-11-05 2010-05-27 Schering Corp Moduladores de gamma secretasa.
JP2009119088A (ja) 2007-11-16 2009-06-04 Hoya Corp 内視鏡用バイポーラ高周波処置具
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009097970A1 (de) 2008-02-05 2009-08-13 Sanofi-Aventis Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
WO2009119088A1 (ja) 2008-03-25 2009-10-01 武田薬品工業株式会社 複素環化合物
JP2009248543A (ja) 2008-04-11 2009-10-29 Fujifilm Corp 光情報記録媒体および情報記録方法
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
FR2933698A1 (fr) 2008-07-09 2010-01-15 Servier Lab Nouveaux derives de benzothiadiazines cycloalkylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CN102149407A (zh) * 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
AU2009313527A1 (en) 2008-11-06 2010-05-14 Merck Sharp & Dohme Corp. Gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
FR2943342B1 (fr) 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2010140339A1 (ja) 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
WO2011007756A1 (ja) 2009-07-13 2011-01-20 武田薬品工業株式会社 複素環化合物及びその用途
WO2011036885A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
WO2011036889A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
US9150591B2 (en) 2010-08-10 2015-10-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2014152917A2 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv Physiological ligands for gpr139
MD20170011A2 (ro) 2014-08-06 2017-08-31 Pfizer Inc. Compuşi imidazopiridazinici
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
WO2020081999A1 (en) 2018-10-18 2020-04-23 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2020097609A1 (en) 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
CA3134545A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
JP2022547952A (ja) 2019-09-16 2022-11-16 ノバルティス アーゲー Ｂｒｄ９二機能性分解誘導薬及びその使用方法
CR20220160A (es) 2019-09-16 2022-06-16 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
WO2021224680A1 (en) 2020-05-08 2021-11-11 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a gpr139 agonist
US20230310441A1 (en) 2020-09-21 2023-10-05 Takeda Pharmaceutical Company Treatment for schizophrenia

Also Published As

Publication number Publication date
TWI873185B (zh) 2025-02-21
CR20220160A (es) 2022-06-16
IL291181A (en) 2022-05-01
WO2021055326A1 (en) 2021-03-25
CO2022004684A2 (es) 2022-07-08
EP4031552A1 (en) 2022-07-27
CN114728975A (zh) 2022-07-08
MX2022003177A (es) 2022-04-06
US12370192B2 (en) 2025-07-29
PH12022550597A1 (en) 2024-03-04
EP4031552C0 (en) 2024-11-06
IL291181B1 (en) 2025-05-01
DOP2022000057A (es) 2022-06-30
AU2020348675B2 (en) 2025-11-20
BR112022004819A2 (pt) 2022-06-07
AR119971A1 (es) 2022-01-26
AU2020348675A1 (en) 2022-04-14
HUE069908T2 (hu) 2025-04-28
PL4031552T3 (pl) 2025-03-17
JOP20220063A1 (ar) 2023-01-30
RS66463B1 (sr) 2025-02-28
JP7566888B2 (ja) 2024-10-15
IL291181B2 (en) 2025-09-01
KR20220063228A (ko) 2022-05-17
US20230028114A1 (en) 2023-01-26
ECSP22020159A (es) 2022-05-31
EP4031552B1 (en) 2024-11-06
KR102924294B1 (ko) 2026-02-09
ES2997267T3 (en) 2025-02-14
JP2022548602A (ja) 2022-11-21
PE20221341A1 (es) 2022-09-13
HRP20250088T1 (hr) 2025-03-28
TW202124386A (zh) 2021-07-01

Similar Documents

Publication Publication Date Title
CA3150508A1 (en) Azole-fused pyridazin-3(2h)-one derivatives
KR102824407B1 (ko) Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
CN114394966B (zh) 吡啶并嘧啶酮cdk2/4/6抑制剂
EP3448386B1 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
EP2943198B1 (en) 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
JP6494622B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
CA3219215A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
MX2014010584A (es) Compuestos a base de imidazo[1,2,b]piridazina, composiciones que los comprenden, y metodos para su uso.
CA2935867A1 (en) Heteroaryls and uses thereof
CA2832291A1 (en) Pyrrolo[2,3-d)pyrimidine tropomyosin-related kinase inhibitors
CA3020287A1 (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017024025A1 (en) 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
AU2019228568A1 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
IL298397A (en) Competitive and noncompetitive inhibitors of the muscarinic acetylcholine receptor m5
EA053259B1 (ru) Конденсированные с азолом производные пиридазин-3(2н)-она
HK40076219A (en) Azole-fused pyridazin-3(2h)-one derivatives
HK40076219B (en) Azole-fused pyridazin-3(2h)-one derivatives
CA3137584C (en) 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
JP7775288B2 (ja) ピリミジノン化合物およびその使用
CA3137584A1 (en) 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
NZ615557B2 (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240821

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240821

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240821

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240906

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240906

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240906

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241003

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241105

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241105

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250407

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251007

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260127

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260203

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260203